The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Phase II
GOG-0283: A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND# 120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression. Gynecologic Oncology Group; Hyman, David Michael. (212) 639-2000
Phase III
E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765) Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL). Eastern Cooperative Oncology Group; Shanafelt, Tait D. 507-284-2358
Other Phases
AAML13B7-Q: Prognostic Significance of MMRN1 in Pediatric Acute Myeloid Leukemia (AML). Children’s Oncology Group; Walter, Roland Bruno. (206) 667-3599
AAML13B8-Q: Global Proteomic and Phosphoproteomic Profiling of Normal B Cells Isolated from COG AAML1031 Study Patients in AML Remission. Children’s Oncology Group; Pandey, Akhilesh. (410) 502-6662
ANBL13B9-Q: 3D Nuclear Telomere Organization in Neuroblastoma. Children’s Oncology Group; Mai, Sabine. (204) 787-2135
ANBL13B10-Q: The Role of FGFR4 in Neuroblastoma Pathogenesis. Children’s Oncology Group; Zage, Peter Eric. (832) 824-4615
AREN13B2-Q: Characterization of the Chromosome 11p15 Imprinting Regulation by Epigenetic and Transcriptomic Analyses in Wilms Tumor Patients. Children’s Oncology Group; Michels, Karin B. (617) 732-4895
